Cover Image

FDA regulatory considerations for oncology drug development

Saved in:

Bibliographic Details
Main Authors:	Hanlim Moon (Author), Dae Young Zang (Author), Min‐Hee Ryu (Author), YeonSook Seo (Author), Bitna Oh (Author), Sunjin Hwang (Author), Lee Farrand (Author)
Format:	Book
Published:	Wiley, 2024-08-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
by: Ioana Gherghescu, et al.
Published: (2020)

The FDA's Regulatory Framework for Chimeric Antigen Receptor‐T Cell Therapies
by: Peter Marks
Published: (2019)

Emerging technology trends in regulatory approvals of cancer immunotherapy drugs by the FDA and EMA
by: Maryam Monajati, et al.
Published: (2024)

Regulatory considerations for paediatric drug evaluation in China
by: Hao Zhang, et al.
Published: (2023)

A network of regulatory innovations to improve FDA quality assessments of human drug applications
by: Russie Tran, et al.
Published: (2024)

CARE program: NCI and FDA interagency collaborations to support oncology small business entrepreneurs
by: Monique A. Pond, et al.
Published: (2023)

Regulatory framework of the oncological medical care provision
by: S. N. Tishkina, et al.
Published: (2020)

Biosimilars in Oncology: Latest Trends and Regulatory Status
by: Deeksha Joshi, et al.
Published: (2022)

Consideration of nutrition and sustainability in public definitions of 'healthy' food: an analysis of submissions to the US FDA
by: Emily H Belarmino, et al.
Published: (2024)

FDA's proposed rule and its regulatory impact on emerging and reemerging neglected tropical diseases in the United States.
by: Alberto E Paniz-Mondolfi, et al.
Published: (2024)

FDA's proposed rule and its regulatory impact on emerging and reemerging neglected tropical diseases in the United States
by: Alberto E. Paniz-Mondolfi, et al.
Published: (2024)

Changes in FDA enforcement activities following changes in federal administration: the case of regulatory letters released to pharmaceutical companies
by: Nguyen Diane, et al.
Published: (2013)

Quantitative Approach to Explore Regulatory T Cell Activity in Immuno-Oncology
by: Alejandro Serrano, et al.
Published: (2024)

Immuno-Oncology Medicines: Policy Implications and Economic Considerations
by: Georges Adunlin, et al.
Published: (2019)

Entecavir: A Review and Considerations for Its Application in Oncology
by: Tânia Lourenço, et al.
Published: (2023)

Sunscreen products: Rationale for use, formulation development and regulatory considerations
by: Kiriiri Geoffrey, et al.
Published: (2019)

Practical, regulatory and clinical considerations for development of inhalation drug products
by: Shuguang Hou, et al.
Published: (2015)

Regulatory Considerations for the Mother, Fetus and Neonate in Fetal Pharmacology Modeling
by: Dionna J. Green, et al.
Published: (2021)

Transformation of Pathology Reports Into the Common Data Model With Oncology Module: Use Case for Colon Cancer
by: Ryu, Borim, et al.
Published: (2020)

An Observational Study of Regulatory Violations Related to Online Tobacco Product Marketing and Retailer Responses to US FDA Warning Letters
by: Dorie E. Apollonio, et al.
Published: (2024)

The United States Food and Drug Administration (FDA) regulatory response to combat neglected tropical diseases (NTDs): A review.
by: Sanjana Mukherjee
Published: (2023)

The United States Food and Drug Administration (FDA) regulatory response to combat neglected tropical diseases (NTDs): A review
by: Sanjana Mukherjee
Published: (2023)

Clinical pharmacology information in regulatory submissions and labeling: A comparative analysis of orphan and non‐orphan drugs approved by the FDA
by: Julie Hsieh, et al.
Published: (2022)

Dynamic consent in the digital age of biology: online initiatives and regulatory considerations
by: Wee R, et al.
Published: (2013)

Pragmatic applications of implementation science frameworks to regulatory science: an assessment of FDA Risk Evaluation and Mitigation Strategies (REMS) (2014-2018)
by: Linda Huynh, et al.
Published: (2021)

Translatability of in vitro potency to clinical efficacious exposure: A retrospective analysis of FDA‐approved targeted small molecule oncology drugs
by: Naoki Kotani, et al.
Published: (2023)

Pivotal Considerations for Optimal Deployment of Healthy Volunteers in Oncology Drug Development
by: Mariam A. Ahmed, et al.
Published: (2020)

Landscape analysis of NTD diagnostics and considerations on the development of a strategy for regulatory pathways.
by: Hye Lynn Choi, et al.
Published: (2022)

Sustainability, natural and organic cosmetics: consumer, products, efficacy, toxicological and regulatory considerations
by: Bruno Fonseca-Santos, et al.
Published: (2015)

Adaptation for Regulatory Application: A Content Analysis of FDA Risk Evaluation and Mitigation Strategies Assessment Plans (2014-2018) Using RE-AIM
by: Gita A. Toyserkani, et al.
Published: (2020)

Health Canada Usage of Real World Evidence (RWE) in Regulatory Decision Making compared with FDA/EMA usage based on publicly available information
by: Catherine Lau, et al.
Published: (2022)

Research biopsies in the context of early phase oncology studies: clinical and ethical considerations
by: Matilde Saggese, et al.
Published: (2013)

Race and Ethnicity in Real-World Data Sources: Considerations for Medical Device Regulatory Efforts
by: Michelle E. Tarver MD, PhD
Published: (2021)

Practical considerations for navigating the regulatory landscape of non-clinical studies for clinical translation of radiopharmaceuticals
by: Aruna Korde, et al.
Published: (2022)

Postbiotics in the medical field under the perspective of the ISAPP definition: scientific, regulatory, and marketing considerations
by: Gabriel Vinderola, et al.
Published: (2023)

3D cell culture models: Drug pharmacokinetics, safety assessment, and regulatory consideration
by: Hongbing Wang, et al.
Published: (2021)

Polymeric Micelles for Breast Cancer Therapy: Recent Updates, Clinical Translation and Regulatory Considerations
by: Vijayabhaskarreddy Junnuthula, et al.
Published: (2022)

Ocular adverse events associated with antibody-drug conjugates in oncology: a pharmacovigilance study based on FDA adverse event reporting system (FAERS)
by: KaiLi Mao, et al.
Published: (2024)

Liver transplantation in a child with acute liver failure resulting from drug rash with eosinophilia and systemic symptoms syndrome
by: Seung Min Song, et al.
Published: (2013)

FDA and EMA Oversight of Disruptive Science on Application of Finite Absorption Time (F.A.T.) Concept in Oral Drug Absorption: Time for Scientific and Regulatory Changes
by: Elias Toulitsis, et al.
Published: (2024)